Methods for expected value of information analysis in complex health economic models: developments on the health economics of beta interferon and glatiramer acetate for multiple sclerosis

首页> 外文期刊>Health technology assessment: HTA >Methods for expected value of information analysis in complex health economic models: developments on the health economics of beta interferon and glatiramer acetate for multiple sclerosis

【24h】

Methods for expected value of information analysis in complex health economic models: developments on the health economics of beta interferon and glatiramer acetate for multiple sclerosis

机译：复杂卫生经济模型中信息分析预期价值的方法：β干扰素和醋酸格拉替雷用于多发性硬化症的卫生经济学进展

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Health technology assessment: HTA》 |2004年第27期|共页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类放射卫生;
关键词

相似文献

外文文献
中文文献
专利

1. HEALTH ECONOMIC EVALUATION OF INTERFERON BETA 1B VERSUS 1A FOR PATIENTS DIAGNOSED WITH RELAPSING REMITTING MULTIPLE SCLEROSIS [J] . Greene M., Greene N. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第3期

机译：干扰素释放多发性硬化症诊断患者的干扰素β1B对1A健康经济评价
2. Convergence yet Continued Complexity: A Systematic Review and Critique of Health Economic Models of Relapsing-Remitting Multiple Sclerosis in the United Kingdom [J] . Allen Felicity, Montgomery Stephen, Maruszczak Maciej, Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2015,第6期

机译：趋同但仍在继续的复杂性：英国复发缓解型多发性硬化症的卫生经济学模型的系统评价和评论
3. Convergence yet Continued Complexity: A Systematic Review and Critique of Health Economic Models of Relapsing-Remitting Multiple Sclerosis in the United Kingdom [J] . Allen Felicity, Montgomery Stephen, Maruszczak Maciej, Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2015,第6期

机译：融合仍然是持续的复杂性：在英国复发 - 储存多发性多发症的卫生经济模型的系统审查和批判
4. Multiscale entropy derived complexity index analysis demonstrates significant mediolateral sway in persons with multiple sclerosis compared to healthy controls [C] . Mark S. Etzelmueller, Siew-Mei Yap, Clodagh O’Keeffe, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2020

机译：多尺度熵衍生的复杂性指数分析表明，与健康对照组相比，多发性硬化症患者的中外侧摇摆明显
5. Hepatitis C in the Post-Interferon Era: Selected Essays in Health Economics [D] . McGinnis, Justin J. 2017

机译：干扰素时代的丙型肝炎：卫生经济学中的选定论文
6. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. [O] . G J Melendez-Torres, Peter Auguste, Xavier Armoiry, -1

机译：β-干扰素和醋酸格拉替雷治疗多发性硬化症的临床效果和成本效益：系统评价和经济评价。
7. PND76 - THE ECONOMIC CONSEQUENCES OF BENEFITS OF DELAYED-RELEASE DIMETHYL FUMARATE TREATMENT VERSUS BETA INTERFERONS AND GLATIRAMER ACETATE ON ABILITY TO WORK OF MULTIPLE SCLEROSIS PATIENTS IN ITALY [O] . FS Mennini, A Marcellusi, G Casamassima 2018

机译：PND76 - 延迟释放二甲基富马特治疗的经济后果与β干扰素和醋酸乙醇酸酯对意大利多发性硬化症患者工作的能力

Methods for expected value of information analysis in complex health economic models: developments on the health economics of beta interferon and glatiramer acetate for multiple sclerosis

著录项

相似文献

相关主题

期刊订阅